Chime Biologics and Waterstone announce a strategic partnership to strengthen the development and manufacturing of antibody drug conjugates (ADC).

Chime Biologics and Waterstone Pharmaceuticals announce a strategic partnership to provide integrated services to the global antibody drug conjugate (ADC) industry.
Chime Biologics will leverage its CMC biologics expertise to manage antibody intermediates, ADC drug substances and drug products, while Waterstone will deliver the linker payload.

WUHAN, China, November 12, 2024 /PRNewswire/ — Chime Biologics, a leading global CDMO that enables the success of its biologics partners, and Waterstone, a trusted partner to its global customers through continuous improvement and innovation to ensure high quality and sustainable service, today announced a strategic partnership known in providing integrated services to the antibody drug conjugate (ADC) industry worldwide.

Through this collaboration, Chime Biologics and Waterstone will provide ADC developers with a comprehensive IND-enabling and clinical trial solution. Leveraging its CMC expertise in biologics, Chime Biologics will lead process development for antibody intermediates, ADC drug substances and drug products, as well as cGMP manufacturing. Waterstone will deliver the linker payload, an important intermediate in the ADC manufacturing process.

Dr. Faming Zhang, CEO of Waterstone commented: “Our partnership with Chime Biologics is a significant milestone for Waterstone. Your expertise in antibody drug development and GMP manufacturing will be critical as we expand into global markets and further develop our assets. We are happy about it.” collaboration, the offers a bright future for our company and the entire ADC industry.”

Dr. Jimmy WeiPresident of Chime Biologicsadded: “We are delighted to begin this strategic collaboration with Waterstone. Currently, Chime Biologics has started implementing several ADC projects. This partnership will significantly advance our innovation and growth in the ADC.” Field. We're looking forward to it explore the limitless possibilities of ADC together with Waterstone.”

About Waterstone

Waterstone Pharmaceuticals was founded and led by a dedicated, decades-long professional team of Global Pharma Industrial eExperience. The company focuses on the research and development and manufacturing of polymer drugs and high-potency small molecules, and specializes in the fields of polymer drugs, diabetes and ADC small molecules. Waterstone has established a long-term and stable cooperative relationship with well-known pharmaceutical companies around the world. The production site has been inspected multiple times by the FDA and offers a fully integrated CDMO/MAH services from research and development to commercial production. Further information can be found at: www.waterstonepharma.com.

About Chime Biologics

Chime Biologics is a leading global CDMO that has launched the world's first modular biopharmaceutical facility, KUBio, to strengthen the success of its biologics partners throughout the entire process from cell line development to commercial manufacturing. Rely on cell line development and advanced technology in our Shanghai Innovation Center, as well as proven success in IND enablement through BLA submission with us Wuhan Chime Biologics provides a one-stop CMC solution to biopharmaceutical customers around the world. We share a common goal of making cutting-edge biomedicine affordable and accessible to all patients worldwide, furthering our commitment to human health. For more information, visit: www.chimebiologics.com.

SOURCE Chime Biologics